Celecoxib

Speaker 1...and this brings us to celecoxib, a COX-2 selective NSAID. It’s effective for pain, but its long-term effects on aging and mortality warrant careful consideration.

Speaker 2Exactly. The anti-inflammatory pathway celecoxib acts on, prostaglandins, are crucial. But the inflammation it's designed to reduce is also complexly linked to aging itself.

Speaker 1Right. One study in *Osteoarthritis and Cartilage* from 2021, for example, highlighted a significant difference. Oral celecoxib, taken regularly, was associated with higher risks of all-cause mortality, cardiovascular disease, and gastrointestinal bleeding compared to topical NSAIDs. Topical forms showed a hazard ratio of 0.59 for all-cause mortality.

Speaker 2That’s a notable distinction. The delivery method clearly impacts the systemic effects. And we know chronic inflammation, particularly high levels of inflammatory markers like IL-6, are linked to worse outcomes. *Experimental Gerontology* in 2015 found serum IL-6 had a robust dose-response relationship with all-cause mortality in the oldest old.

Speaker 1So, while celecoxib aims to reduce inflammation and pain, the long-term systemic impact of *oral* administration, and its effect on biological aging markers or epigenetic clocks, isn't fully established. We have these signals about mortality and specific harms.

Speaker 2We definitely do. And while pain relief is crucial for quality of life, understanding the full picture of how these treatments intersect with the aging process and overall longevity is still an active area of research. It's about weighing benefits against potential long-term risks, and for many, supervised use provides necessary relief.